Menu Search
Equities

Merck KGaA

MRKX:GER

Merck KGaA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)166.85
  • Today's Change0.85 / 0.51%
  • Shares traded264.46k
  • 1 Year change+5.97%
  • Beta0.6821
Data delayed at least 15 minutes, as of Sep 19 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy7
Outperform12
Hold2
Sell0
Strong Sell0

Share price forecast in EUR

The 18 analysts offering 12 month price targets for Merck KGaA have a median target of 188.50, with a high estimate of 205.00 and a low estimate of 165.00. The median estimate represents a 12.98% increase from the last price of 166.85.
High22.9%205.00
Med13.0%188.50
Low-1.1%165.00

Dividends in EUR

In 2023, Merck KGaA reported a dividend of 2.20 EUR, equaling last years dividend. The 15 analysts covering the company expect dividends of 2.30 EUR for the upcoming fiscal year, an increase of 4.45%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in EUR

On Aug 01, 2024, Merck KGaA reported 2nd quarter 2024 earnings of 2.20 per share. This result exceeded the 1.97 consensus of the 6 analysts covering the company and was the same as last year's 2nd quarter results.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate+0.40%
Merck KGaA reported annual 2023 earnings of 8.49 per share on Mar 07, 2024.
Average growth rate+12.60%
More ▼

Revenue history & estimates in EUR

MERCK Kommanditgesellschaft auf Aktien had 2nd quarter 2024 revenues of 5.35bn. This bettered the 5.28bn consensus of the 8 analysts covering the company. This was 1.11% above the prior year's 2nd quarter results.
Average growth rate+0.27%
MERCK Kommanditgesellschaft auf Aktien had revenues for the full year 2023 of 20.99bn. This was 5.57% below the prior year's results.
Average growth rate+7.05%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.